Blueprint Medicines Corporation Cost of Revenue | BPMC

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Blueprint Medicines Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
20.2 M	8.54 M	17.8 M	17.9 M	425 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
20.2 M	425 K	13 M

Quarterly Cost of Revenue Blueprint Medicines Corporation

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.8 M	-	1.93 M	7.59 M	3.19 M	-	2.78 M	2.32 M	3.18 M	-	3 M	4.89 M	5.08 M	-	3.79 M	6.49 M	102 K	-	146 K	127 K	24 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.59 M	24 K	2.97 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
Outlook Therapeutics OTLK	1.36 M	$ 0.6	0.42 %	$ 20.9 M	USA
Puma Biotechnology PBYI	58.2 M	$ 9.67	1.68 %	$ 484 M	USA
Pfizer PFE	16.1 B	$ 27.41	0.02 %	$ 156 B	USA
Pharming Group N.V. PHAR	20.6 M	$ 9.8	0.51 %	$ 6.75 B	Niderland
Phathom Pharmaceuticals PHAT	22.6 M	$ 6.7	1.77 %	$ 489 M	USA
Protalix BioTherapeutics PLX	27 M	$ 2.71	0.37 %	$ 213 M	Israel
PainReform Ltd. PRFX	70 K	$ 0.88	0.04 %	$ 570 K	Israel
PTC Therapeutics PTCT	12.1 M	$ 63.65	0.3 %	$ 5.06 B	USA
uniQure N.V. QURE	1.69 M	$ 22.8	0.39 %	$ 1.31 B	Niderland
Regeneron Pharmaceuticals REGN	403 M	$ 726.47	0.05 %	$ 76 B	USA
Rafael Holdings RFL	154 K	$ 1.47	0.65 %	$ 43.3 M	USA
REGENXBIO RGNX	33.6 M	$ 7.76	4.44 %	$ 400 M	USA
Rigel Pharmaceuticals RIGL	19.6 M	$ 47.79	1.36 %	$ 860 M	USA
Rhythm Pharmaceuticals RYTM	19.5 M	$ 92.45	0.24 %	$ 6.01 B	USA
Seer SEER	8.11 M	$ 2.33	3.56 %	$ 129 M	USA
SIGA Technologies SIGA	29.7 M	$ 3.48	2.96 %	$ 249 M	USA
Silence Therapeutics plc SLN	10.3 M	$ 10.14	0.78 %	$ 1.44 B	Britain
SELLAS Life Sciences Group SLS	100 K	$ 11.63	3.62 %	$ 1.27 B	USA
Soligenix SNGX	119 K	$ 0.36	0.6 %	$ 1.87 M	USA
Sanofi SNY	13 B	$ 39.51	1.19 %	$ 48.2 B	France